Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR

Autor: Aijiang Nuerlan, Zhiping Ma, Wei Zhang, Jing Niu, Wenli Cui, Si-Jing Li, Xinxia Li, Gulinaer Abulajiang, Hai-Xia Gao
Rok vydání: 2020
Předmět:
Adult
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Mutation rate
Lymphocyte
Biology
Gene mutation
Polymerase Chain Reaction
Biochemistry
droplet digital PCR
Central Nervous System Neoplasms
03 medical and health sciences
0302 clinical medicine
Mutation Rate
Internal medicine
Genetics
medicine
Humans
Digital polymerase chain reaction
Correlation of Data
Molecular Biology
Survival analysis
Aged
Aged
80 and over
NF-κB pathway
Cancer
Articles
Microfluidic Analytical Techniques
Middle Aged
Prognosis
medicine.disease
Immunohistochemistry
Survival Analysis
diffuse large B cell lymphoma
030104 developmental biology
medicine.anatomical_structure
myeloid differentiation factor 88 L265P
030220 oncology & carcinogenesis
Myeloid Differentiation Factor 88
Molecular Medicine
Female
Lymphoma
Large B-Cell
Diffuse
Diffuse large B-cell lymphoma
Follow-Up Studies
Zdroj: Molecular Medicine Reports
ISSN: 1791-3004
1791-2997
DOI: 10.3892/mmr.2020.11186
Popis: To assess the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) expression and mutational status in diffuse large B cell lymphoma (DLBCL), a total cohort of 100 patients with DLBCL were studied using immunohistochemistry (IHC) and droplet digital polymerase chain reaction (DDPCR), and the association between MYD88 expression and clinicopathological parameters was analyzed. Overall, the positive expression rate of MYD88 protein was 38% and the gene mutation rate was 29%. The positive expression and mutation rates were the highest in the primary central nervous system lymphomas (58.33 and 66.67%, respectively). The coincidence rate of the results of MYD88 expression between IHC and DDPCR results was 73% (73/100). Univariate survival analysis showed that age (≥60 years old), high neutrophil/lymphocyte count ratio, low lymphocyte count, c-Myc ≥40%, positive MYD88 protein expression, and gene mutation were associated with poorer prognosis rates. Multivariate survival analysis revealed that MYD88 expression was an independent prognostic factor affecting overall survival. In conclusion, the results of this study demonstrated that MYD88 mutation was a valuable index to evaluate the prognosis of DLBCL. DDPCR can be used as a method for detecting MYD88 mutations, although it was not completely consistent with the results of IHC.
Databáze: OpenAIRE
Externí odkaz: